Publication date: 12/06/2018
argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that it will host a key opinion leader (KOL) breakfast meeting focused on the potential of efgartigimod to treat patients with immune thrombocytopenia (ITP) on Tuesday, June 19, 2018, from 8:30 a.m. to 10:30 a.m. ET in New York City.
The event will feature guest speaker Catherine Broome, MD, of Georgetown University Hospital, who will highlight the treatment landscape and unmet need in ITP. Additionally, members of our management will present on the market opportunity, biological rationale of efgartigimod in ITP and trial design of the ongoing Phase 2 study.
A live webcast of the event will be available via this link. The webcast will be archived following the event and available for download on our website at www.argenx.com.
argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE Antibody(TM) Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates.